Navamedic
Sitemap
- Portfolio
- Investor relations
-
Newsroom
- 2018
-
2017
- December
-
November
- Navamedic ASA: Enters into long-term agreement for distribution of GoNitro®* in the Nordics
- Navamedic ASA: Q3 2017 results
- Navamedic ASA Q3 2017 Presentation
- Navamedic ASA presentation Q3 2017
- Navamedic ASA: Invitation to presentation of third quarter results 2017
- Navamedic ASA: Invitation to presentation of third quarter results 2017
- August
- July
- June
-
May
- Navamedic ASA: Granted European patent for Sippi® base technology
- Navamedic ASA: Notice of Annual General Meeting
- Navamedic ASA: Q1 2017 results
- Navamedic ASA: Invitation to presentation of first quarter results 2017
- Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®
- Navamedic ASA: Enters into partnership agreement with Orexigen Therapeutics for Nordic launch of Mysimba®
- April
- March
- January
-
2016
- November
- October
- September
- August
- July
-
June
- Avholdt generalforsamling - korrigert oppmøteprosent
- Disclosure of voting rights in connection with Annual General Meeting 2016
- Avholdt ordinær generalforsamling
- Annual general meeting held
- Navamedic ASA - Registration of share capital increase
- Notification of Mandatory Trade
- Navamedic ASA:
- Navamedic: Announces new patent for Sippi line extension
- Flaggemelding
- Navamedic: Enters into strategic partnership and 8-year distribution agreement with TopRidge Pharma Limited
- Valgkomiteens instilling til styresammensetning på generalforsamling 20 juni 2016
- Disclosure of large shareholding
-
May
- Korrigering: New scheduled Annual General Meeting 20 June
- Utsettelse av ordinær generalforsamling
- Valgkomiteens innstilling til godtgjørelse til styret, revisjonsutvalget og valgkomiteen.
- Navamedic ASA : Q1 2016 Results
- Notice of Annual General Meeting 26 May
- Invitation to presentation of first quarter results 2016
- April
- March
- February
- January
- About Navamedic
- Contact